{
    "root": "385b0750-5e02-416e-b01d-2e26e67da2bd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250310",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)",
            "code": "87Y6436BKR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26092"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        }
    ],
    "indications": {
        "text": "divalproex sodium delayed-release tablet anti-epileptic indicated : treatment manic episodes associated bipolar disorder ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "divalproex sodium delayed-release tablets administered orally divided doses . divalproex sodium delayed-release tablets swallowed whole crushed chewed ( 2.1 , 2.2 ) . mania : initial dose 750 mg daily , increasing rapidly possible achieve therapeutic response desired plasma level ( 2.1 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . migraine : recommended starting dose 250 mg twice daily , thereafter increasing maximum 1,000 mg/day needed ( 2.3 ) .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "hepatic disease significant hepatic dysfunction ( 4 , 5.1 ) known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ) ( 4 , 5.1 ) suspected polg-related disorder children two years age ( 4 , 5.1 ) known hypersensitivity ( 4 , 5.12 ) urea cycle disorders ( 4 , 5.6 ) prophylaxis migraine headaches : pregnant women , women childbearing potential using effective contraception ( 4 , 8.1 )",
    "indications_original": "Divalproex sodium delayed-release tablet is an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar      disorder ( 1.1 ) Monotherapy and adjunctive therapy of complex partial      seizures and simple and complex absence seizures; adjunctive therapy in      patients with multiple seizure types that include absence seizures      ( 1.2 ) Prophylaxis of migraine headaches      ( 1.3 )",
    "contraindications_original": "Divalproex sodium delayed-release tablets are administered      orally in divided doses. Divalproex sodium delayed-release tablets should      be swallowed whole and should not be crushed or chewed ( 2.1 , 2.2 ). Mania: Initial dose is 750 mg daily, increasing as rapidly      as possible to achieve therapeutic response or desired plasma level ( 2.1 ).      The maximum recommended dosage is 60 mg/kg/day ( 2.1 , 2.2 ). Complex Partial Seizures: Start at 10 to 15 mg/kg/day,      increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal      clinical response; if response is not satisfactory, check valproate plasma      level; see full prescribing information for conversion to monotherapy ( 2.2 ).      The maximum recommended dosage is 60 mg/kg/day ( 2.1 , 2.2 ). Absence Seizures: Start at 15 mg/kg/day, increasing at 1      week intervals by 5 to 10 mg/kg/day until seizure control or limiting side      effects ( 2.2 ). The maximum recommended dosage      is 60 mg/kg/day ( 2.1 , 2.2 ). Migraine: The recommended starting dose is 250 mg twice      daily, thereafter increasing to a maximum of 1,000 mg/day as needed ( 2.3 ).",
    "adverseReactions_original": "Hepatic      disease or significant hepatic dysfunction ( 4 , 5.1 ) Known      mitochondrial disorders caused by mutations in mitochondrial DNA      polymerase \u03b3 (POLG) ( 4 , 5.1 ) Suspected      POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known      hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle      disorders ( 4 , 5.6 ) Prophylaxis      of migraine headaches: Pregnant women, women of childbearing potential not      using effective contraception ( 4 , 8.1 )",
    "drug": [
        {
            "name": "Divalproex Sodium"
        }
    ]
}